13th Jul 2015 07:59
LONDON (Alliance News) - Pharmaceutical company Alliance Pharma PLC on Monday said it is trading in line with its expectations and said its Hydromol skin care brand has performed well.
Alliance said it expects sales in the first half to the end of June to be GBP22.8 million, up from GBP21.4 million a year earlier, in line with its expectations. The sales revenue has been pushed higher by a 10% year-on-year growth in Hydromol sales, it said.
Its recently acquired MacuShield eye care supplement is performing in line with Alliance's expectations, and the company said it expects supplies of its ImmuCyst bladder cancer drug to start up again in the second half. The company has been unable to supply ImmuCyst since production was halted at Sanofi SA's manufacturing plant in Canada in mid-2012, after US Food and Drug Administration inspectors cited the plant for mould problems.
Alliance added it is continuing to run the rule over potential acquisitions and remains confident on its outlook for the rest of the year.
It will publish first-half results on September 9.
Shares in Alliance Pharma were up 1.7% to 45.4999 pence on Monday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Alliance Pharma